Diginex Expands Supply Chain End-to-End Product Suite Amid Accelerating Regulatory Pressure
• In a human rights and supply chain due diligence market valued at approximately $3.8 billion in 2025, non-compliance carries material, financial and reputational consequences. • Diginex's Risk-to-Remedy is an end-to-end solution supporting supply chain transparency and risk surfacing to enable faster, evidence-based action and more defensible reporting. • Upcoming enhancements to Diginex's supply chain offering will enable businesses to make smarter decisions, take effective action and measure outcomes. LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- Diginex Limited (NASDAQ: DGNX ), a provider of ESG, sustainability and compliance solutions to institutional and corporate clients, today announced the integration of Risk-to-Remedy as an end-to-end supply chain due diligence solution and introduces the next phase of its supply chain offering. Built on LUMEN for supply chain risk assessment and APPRISE for direct worker engagement, and strengthened by the acquisition of The Remedy Project's expertise in grievance mechanisms and remediation, Risk-to-Remedy integrates worker-level evidence, prioritised remediation and regulator-ready reporting within a single framework, closing the gap between what companies declare and what they can demonstrate. The Regulatory Imperative With 86% of forced labour occurring in the private sector, and modern slavery affecting an estimated 50 million people globally, most compliance tools still rely on supplier declarations and annual audits that fail to capture workers' lived experience, leaving a persistent gap between what companies declare and what is actually occurring. Transparency regimes, including the UK Modern Slavery Act, Australia's Modern Slavery ... Full story available on Benzinga.com
